Editorial: Epidemic-Assistance Investigations by the Centers for Disease Control and Prevention—The First 60 Years

Tekijä O'Brien, Thomas R.
Julkaistu 2011

What Have We Learned from Studies of IFN-λ Variants and Hepatitis C Virus Infection?

Tekijä O'Brien, Thomas R., Jackson, Sarah S.
Julkaisussa J Interferon Cytokine Res (2019)

Recent Decline in Hepatocellular Carcinoma Rates in the United States

Tekijä Shiels, Meredith S., O’Brien, Thomas R.
Julkaisussa Gastroenterology (2020)

IL28B-Genotype Testing Now and in the Era of Direct-Acting Antiviral Agents

Tekijä Morgan, Timothy R., O’Brien, Thomas R.
Julkaistu 2010

Reply: Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C

Tekijä O’Brien, Thomas R., Pfeiffer, Ruth M.
Julkaisussa Open Forum Infect Dis (2015)

Population Genetics and Comparative Genetics of CLDN1, a Gene Involved in Hepatitis C Virus Entry

Tekijä Bekker, Vincent, O’Brien, Thomas R., Chanock, Stephen
Julkaistu 2009

The role of genetics in hepatic fibrosis amongst HCV patients

Tekijä Park, Heiyoung, O’Brien, Thomas R., Rehermann, Barbara
Julkaisussa Hepatology (2018)

Possible Role of Hepatitis D Virus in Severe Hepatitis Related to Hepatitis B Virus Reactivation After Therapy for Chronic Hepatitis C

Tekijä Mahale, Parag, Glenn, Jeffrey S., O’Brien, Thomas R.
Julkaisussa Ann Intern Med (2017)

Interferon-lambda and therapy for chronic hepatitis C virus infection

Tekijä Donnelly, Raymond P., Dickensheets, Harold, O'Brien, Thomas R.
Julkaistu 2011

What makes the hepatitis C virus evolve?

Tekijä O'Brien, Thomas R, Hartmann, Rune, Prokunina-Olsson, Ludmila
Julkaisussa eLife (2019)

IFNL4 Genotype is Associated with Virologic Relapse After 8-Week Treatment with Sofosbuvir, Velpatasvir and Voxilaprevir

Tekijä O’Brien, Thomas R., Kottilil, Shyam, Pfeiffer, Ruth M.
Julkaisussa Gastroenterology (2017)

IFN-λ4: The Paradoxical New Member of the Interferon Lambda Family

Tekijä O'Brien, Thomas R., Prokunina-Olsson, Ludmila, Donnelly, Raymond P.
Julkaistu 2014

Beasley’s 1981 paper: The power of a well-designed cohort study to drive liver cancer research and prevention

Tekijä Koshiol, Jill, Liu, Zhiwei, O’Brien, Thomas R., Hildesheim, Allan
Julkaisussa Cancer Epidemiol (2018)

Subgroup Differences in Response to 8 Weeks of Ledipasvir/Sofosbuvir for Chronic Hepatitis C

Tekijä O'Brien, Thomas R., Lang Kuhs, Krystle A., Pfeiffer, Ruth M.
Julkaisussa Open Forum Infect Dis (2014)

Lymphocyte subsets in hemophilic patients with hepatitis C virus infection with or without human immunodeficiency virus co-infection: a nested cross-sectional study

Tekijä Zhang, Mingdong, O'Brien, Thomas R, Kopp, William C, Goedert, James J
Julkaistu 2005

Re: Pearlman and Ehleben - Hepatitis C Genotype 1 Virus with Low Viral Load and Rapid Virologic Response to Peginterferon/Ribavirin Obviates a Protease Inhibitor

Tekijä Wang, Alan S., Pfeiffer, Ruth M., Morgan, Timothy R., O'Brien, Thomas R.
Julkaistu 2014

No Scientific Basis to Restrict 8 Weeks of Treatment with Ledipasvir/Sofosbuvir to Patients with HCV RNA <6,000,000 IU/ml

Tekijä O’Brien, Thomas R., Feld, Jordan J., Kottilil, Shyam, Pfeiffer, Ruth M.
Julkaisussa Hepatology (2015)

Shortening the duration of therapy for chronic hepatitis C infection

Tekijä Emmanuel, Benjamin, Wilson, Eleanor M, O’Brien, Thomas R, Kottilil, Shyam, Lau, George
Julkaisussa Lancet Gastroenterol Hepatol (2017)

Meeting Overview: Interferon Lambda—Disease Impact and Therapeutic Potential

Tekijä O'Brien, Thomas R., Young, Howard A., Donnelly, Raymond P., Prokunina-Olsson, Ludmila
Julkaisussa J Interferon Cytokine Res (2019)

Race or Genetic Makeup for HCV Treatment Decisions?

Tekijä O’Brien, Thomas R., Kottilil, Shyam, Feld, Jordan J., Morgan, Timothy R., Pfeiffer, Ruth M.
Julkaisussa Hepatology (2017)